Zevra Therapeutics Inc (ZVRA)
6.92
-0.39
(-5.34%)
USD |
NASDAQ |
Sep 27, 16:00
6.92
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Research and Development Expense (TTM): 46.33M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 46.33M |
| March 31, 2024 | 43.24M |
| December 31, 2023 | 39.62M |
| September 30, 2023 | 34.93M |
| June 30, 2023 | 28.01M |
| March 31, 2023 | 43.04M |
| December 31, 2022 | 37.47M |
| September 30, 2022 | 33.73M |
| June 30, 2022 | 30.59M |
| March 31, 2022 | 10.98M |
| December 31, 2021 | 10.16M |
| September 30, 2021 | 10.41M |
| June 30, 2021 | 9.876M |
| March 31, 2021 | 8.982M |
| December 31, 2020 | 8.843M |
| September 30, 2020 | 8.254M |
| June 30, 2020 | 10.16M |
| March 31, 2020 | 13.01M |
| December 31, 2019 | 19.42M |
| September 30, 2019 | 23.25M |
| Date | Value |
|---|---|
| June 30, 2019 | 32.97M |
| March 31, 2019 | 38.65M |
| December 31, 2018 | 41.76M |
| September 30, 2018 | 40.99M |
| June 30, 2018 | 33.95M |
| March 31, 2018 | 28.12M |
| December 31, 2017 | 20.59M |
| September 30, 2017 | 23.02M |
| June 30, 2017 | 21.01M |
| March 31, 2017 | 21.35M |
| December 31, 2016 | 20.47M |
| September 30, 2016 | 17.22M |
| June 30, 2016 | 17.27M |
| March 31, 2016 | 15.05M |
| December 31, 2015 | 13.93M |
| September 30, 2015 | 15.13M |
| June 30, 2015 | 14.05M |
| March 31, 2015 | 13.00M |
| December 31, 2014 | 11.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
8.254M
Minimum
Sep 2020
46.33M
Maximum
Jun 2024
23.51M
Average
21.33M
Median
Research and Development Expense (TTM) Benchmarks
| Vanda Pharmaceuticals Inc | 78.75M |
| BioCardia Inc | 5.069M |
| Verrica Pharmaceuticals Inc | 20.10M |
| Xeris Biopharma Holdings Inc | 25.00M |
| Crinetics Pharmaceuticals Inc | 201.10M |